DATA GRAPHICS | Data Byte
Plus: Roche withdraws an application for Tecentriq combo, and AbbVie for Durysta
By Gunjan Ohri, Data Content Analyst
September 20, 2024 11:30 PM UTC
As competition comes for AbbVie’s FOLR1-targeting ADC Elahere in ovarian cancer, EMA’s CHMP issued positive opinion for the therapy. At its September meeting, the committee also recommended approval four other new therapies and label expansions for at least 10. AbbVie and Roche withdrew applications.
The CHMP recommendation for Elahere mirvetuximab soravtansine from AbbVie Inc. (NYSE:ABBV) is for use of the antibody-drug conjugate (ADC) to treat FOLR1-positive epithelial ovarian, fallopian tube and primary peritoneal cancer. In April, FDA granted the product full approval for a similar set of indications, converting its 2022 accelerated approval. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653628/abbvie-s-elahere-gets-chmp-nod-as-competition-advances